Tg(S100b-EGFP/cre/ERT2)22Amc
Transgene Detail
|
Symbol: |
Tg(S100b-EGFP/cre/ERT2)22Amc |
Name: |
transgene insertion 22, Andrew P McMahon |
MGI ID: |
MGI:4849988 |
Synonyms: |
S100b-GCE |
Transgene: |
Tg(S100b-EGFP/cre/ERT2)22Amc Location: unknown
|
Alliance: |
Tg(S100b-EGFP/cre/ERT2)22Amc page
|
|
|
Transgene Type: |
|
Transgenic (Inducible, Recombinase, Reporter) |
Inducer: |
|
tamoxifen |
Mutation: |
|
Insertion
|
|
|
Tg(S100b-EGFP/cre/ERT2)22Amc expression driven by
1 gene
Transgene expression driven by:
Organism |
Driver Gene |
Note |
mouse |
S100b (MGI:98217) |
|
|
|
|
Mutation details: A targeting construct containing the eGFPCreERT2 (GCE) cassette and FRT site flanked Kanamycin/neomycin selection cassette was inserted into the consensus start ATG codon of the gene in a BAC (RP23-213P2). The PGK-Neo/Kan cassette was removed by transient Flpe-recombinase expression. The resulting BAC transgene was microinjected into (C57BL/6 x DBA)F1 donor eggs. Founder line 22 was subsequently established. GFP fluorescence is not detectable by fluorescent microscope examination of whole embryos, bones or neural tube sagittal slices from embryos aged 15.5dpc. Tamoxifen induced cre recombinase activity is detected in a subset of the GFP immunoreactive-positive cells in bone.
(J:159099)
|
|
|
Activity: |
Tissue activity of this recombinase allele
|
Driver:
|
S100b
(mouse)
|
|
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 1 strain available
Cell Lines: 0 lines available
|
|
Original: |
J:159099 McMahon A, et al., Summary of mouse strains characterized by GUDMAP consortium. Unpublished. 2010; |
All: |
1 reference(s) |
|